Repligen CEO says Spectrum acquisition fills gap in bioprocessing product line

By Flora Southey contact

- Last updated on GMT

iStock/istocksdaily
iStock/istocksdaily

Related tags: Monoclonal antibodies, Biotechnology

Repligen Corporation has announced it will acquire filtration-focused Spectrum Pharmaceuticals for approximately $350m (€312m).

California-US-headquartered Spectrum manufactures products employed for the filtration, isolation, purification and concentration of monoclonal antibodies, vaccines, recombinant proteins, diagnostic products and cell therapies.

CEO Tony Hunt said the acquisition, which integrates Spectrum’s portfolio of microfiltration and ultrafiltration-focused hollow fibre cartridges, will simplify production of Repligen’s bioprocessing systems.

At present, Repligen purchases hollow fibre filters for its upstream bioprocessing system, XCell ATF (alternating tangential flow), from Spectrum and other firms via original equipment manufacturer (OEM) agreements.

“This transaction addresses one of the biggest gaps in our XCell ATF ​[alternating tangential flow] product line,”​ he said.

The procurement of these cartridges will improve the Repligen’s filtration business and position in the single-use and continuous manufacturing technologies for bioprocesses market, he added.

“I really believe that Repligen needed to strengthen both its chromatography and filtration portfolio. I think this deal really allows us to do that,”​ said Hunt.

Portfolio progression

Repligen, which manufactures resins to purify monoclonal antibodies, will merge Spectrum’s varied therapeutic portfolio in order to increase market presence.

“The acquisition diversifies Repligen’s markets beyond monoclonal antibody production into vaccine, recombinant protein and gene therapy production,” ​the company said.

Repligen’s CEO told analysts he also plans to cross-sell the firms’ portfolios.

“I am very excited by opportunities for us to cross-sell the combined portfolios for expanded commercial organisation,”​ Hunt said.

While Hunt didn’t provide a timeline on new products, he did say that it would take three to six months to get staff from both firms aligned.

The transaction is expected to be completed in the third quarter of 2017.

Spectrum has 220 employees located in manufacturing sites in North America, a sales and distribution centre in the Netherlands, and commercially across North America, Asia and Europe.

Related news

Show more

Related products

show more

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Downstream Purification of Large Biomolecules

Downstream Purification of Large Biomolecules

Bio-Rad Laboratories | 17-Sep-2018 | Research Study

Our newest strong anion exchange resin provides both high binding capacity and
high recovery, even at high flow rates. A rigid bead complete with...

CadenceILC_610x343

Inline concentration improves process economics

Pall Biotech | 15-Jun-2018 | Case Study

Would you like to enhance your downstream process, increase production capacity and reduce costs? This case study application note demonstrates how implementing...

Related suppliers

Follow us

Products

View more

Webinars